1. Home
  2. NRC vs CAPR Comparison

NRC vs CAPR Comparison

Compare NRC & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRC
  • CAPR
  • Stock Information
  • Founded
  • NRC 1981
  • CAPR 2005
  • Country
  • NRC United States
  • CAPR United States
  • Employees
  • NRC N/A
  • CAPR N/A
  • Industry
  • NRC Biotechnology: Commercial Physical & Biological Resarch
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NRC Health Care
  • CAPR Health Care
  • Exchange
  • NRC Nasdaq
  • CAPR Nasdaq
  • Market Cap
  • NRC 354.5M
  • CAPR 324.6M
  • IPO Year
  • NRC N/A
  • CAPR N/A
  • Fundamental
  • Price
  • NRC $14.65
  • CAPR $6.28
  • Analyst Decision
  • NRC
  • CAPR Strong Buy
  • Analyst Count
  • NRC 0
  • CAPR 8
  • Target Price
  • NRC N/A
  • CAPR $24.75
  • AVG Volume (30 Days)
  • NRC 101.8K
  • CAPR 1.4M
  • Earning Date
  • NRC 10-24-2025
  • CAPR 08-11-2025
  • Dividend Yield
  • NRC 3.27%
  • CAPR N/A
  • EPS Growth
  • NRC N/A
  • CAPR N/A
  • EPS
  • NRC 0.77
  • CAPR N/A
  • Revenue
  • NRC $140,314,000.00
  • CAPR $13,392,150.00
  • Revenue This Year
  • NRC N/A
  • CAPR N/A
  • Revenue Next Year
  • NRC N/A
  • CAPR $6,061.53
  • P/E Ratio
  • NRC $19.08
  • CAPR N/A
  • Revenue Growth
  • NRC N/A
  • CAPR N/A
  • 52 Week Low
  • NRC $9.76
  • CAPR $3.98
  • 52 Week High
  • NRC $22.99
  • CAPR $23.40
  • Technical
  • Relative Strength Index (RSI)
  • NRC 47.80
  • CAPR 36.33
  • Support Level
  • NRC $14.45
  • CAPR $6.17
  • Resistance Level
  • NRC $15.60
  • CAPR $7.30
  • Average True Range (ATR)
  • NRC 0.64
  • CAPR 0.43
  • MACD
  • NRC -0.03
  • CAPR -0.11
  • Stochastic Oscillator
  • NRC 17.05
  • CAPR 4.53

About NRC National Research Corporation (Delaware)

National Research Corp is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare providers, payers, and other healthcare organizations. Its portfolio of solutions represents a set of capabilities that individually and collectively provide value to clients. It operates in the United States and Canada, of which key revenue is derived from the United States.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: